title: Antibody-drug conjugates: an emerging modality for the treatment of cancer.
abstract: Antibody-drug conjugates (ADCs) offer promise as a therapeutic modality that can potentially reduce the toxicities and poor therapeutic indices caused by the lack of specificity of conventional anticancer therapies. ADCs combine the potency of cytotoxic agents with the target selectivity of antibodies by chemically linking a cytotoxic payload to an antibody, potentially creating a synthetic molecule that will deliver targeted antitumor therapy that is both safe and efficacious. The ADC repertoire contains a range of payload molecules, antibodies, and linkers. Two ADC molecules, Kadcyla® and Adcetris®, have been approved by the FDA, and many more are currently in clinical development.
authors.affiliation: Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc, Pearl River, New York.
authors.forename: Mauricio
authors.initials: M
authors.lastname: Leal
authors.forename: Puja
authors.initials: P
authors.lastname: Sapra
authors.forename: Sara A
authors.initials: SA
authors.lastname: Hurvitz
authors.forename: Peter
authors.initials: P
authors.lastname: Senter
authors.forename: Alan
authors.initials: A
authors.lastname: Wahl
authors.forename: Melissa
authors.initials: M
authors.lastname: Schutten
authors.forename: Dhaval K
authors.initials: DK
authors.lastname: Shah
authors.forename: Nahor
authors.initials: N
authors.lastname: Haddish-Berhane
authors.forename: Omar
authors.initials: O
authors.lastname: Kabbarah
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D017277:Drug Approval; D015195:Drug Design; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry / Q000627:therapeutic use*; D008453:Maytansine / Q000031:analogs & derivatives / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy*; D000068878:Trastuzumab; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D008453:Maytansine; D000079963:Brentuximab Vedotin; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine
keywords: antibody-drug conjugate; cancer therapy; linker; payload; quantitative translational systems pharmacology